**PRESS RELEASE**
6th January 2015, Hyderabad

# Aurobindo Pharma receives USFDA Approval for Valsartan Tablets

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Valsartan Tablets USP, 40mg, 80mg, 160mg and 320mg (ANDA 202223). The product is ready for launch.

Valsartan Tablets USP, 40mg, 80mg, 160mg and 320mg are the generic equivalent to the reference listed drug product (RLD) Diovan® Tablets, 40mg, 80mg, 160mg and 320mg respectively of Novartis Pharmaceuticals Corporation (Novartis) and indicated for the treatment of hypertension, to lower blood pressure. The product falls under the therapeutic category of CVS (Cardio Vascular) has a market size of approximately US$ 2 Billion for the twelve months ending October 2014 according to IMS.

Aurobindo now has a total of 195 ANDA approvals (170 Final approvals including 7 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA

**About Aurobindo Pharma Limited:**
Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

**For further information, please contact:**
Investor Relations
Aurobindo Pharma Limited

Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com
Website : www.aurobindo,.com

Corporate Off: WaterMark Building, Level-1
Plot No.11, Survey No. 9
Kondapur, Hitech City, Hyderabad

Reg Off: Plot No. 2, Maitrivihar
Ameerpet, Hyderabad